SHPH SHUTTLE PHARMACEUTICALS HOLDINGS INC Product Launches 8-K Filing 2025 - Clinical Trial Update Shuttle Pharmaceuticals announced 25% enrollment in its Phase 2 clinical trial for Ropidoxuridine, targeting glioblastoma patients, with plans to randomize 40 patients into two dose levels to find the optimal dose.Get access to all SEC 8-K filings of the SHUTTLE PHARMACEUTICALS HOLDINGS INC